(Q35127246)

6 August 2017

1 reference

title

Minireview: adiposity, inflammation, and atherogenesis (English)

1 reference

https://api.crossref.org/works/10.1210/EN.2003-0285

6 August 2017

Minireview: Adiposity, Inflammation, and Atherogenesis (English)

1 reference

2 January 2024

1 reference

https://api.crossref.org/works/10.1210/EN.2003-0285

2 January 2024

author name string

Christopher J. Lyon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12746274

reference URL

2 January 2024

Ronald E. Law

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12746274

reference URL

2 January 2024

Willa A. Hsueh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12746274

reference URL

2 January 2024

language of work or name

English

0 references

publication date

1 June 2003

1 reference

full work available at URL

6 August 2017

published in

Endocrinology

1 reference

6 August 2017

volume

144

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

2195-2200

1 reference

Adipose tissue as an endocrine organ

6 August 2017

cites work

https://api.crossref.org/works/10.1210/EN.2003-0285

1

1 reference

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

2

1 reference

Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

3

1 reference

Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

5

1 reference

Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

6

1 reference

Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

9

1 reference

Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

11

1 reference

Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

13

1 reference

Relationship between changes in serum leptin levels and blood pressure after weight loss

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

14

1 reference

Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

16

1 reference

Chronic leptin infusion increases arterial pressure

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

17

1 reference

Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

18

1 reference

Correction of diet-induced hyperglycemia, hyperinsulinemia, and skeletal muscle insulin resistance by moderate hyperleptinemia.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

19

1 reference

Leptin-replacement therapy for lipodystrophy.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

20

1 reference

The hormone resistin links obesity to diabetes

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

21

1 reference

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

22

1 reference

Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

23

1 reference

Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

24

1 reference

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

25

1 reference

Weight Reduction Increases Plasma Levels of an Adipose-Derived Anti-Inflammatory Protein, Adiponectin

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

26

1 reference

Changing concepts of atherogenesis

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

27

1 reference

Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

28

1 reference

Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

29

1 reference

Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

30

1 reference

Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

31

1 reference

Vascular cell adhesion molecule 1: contrasting transcriptional control mechanisms in muscle and endothelium

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

33

1 reference

Inhibition of phorbol ester-induced cellular adhesion by competitive binding of NF-kappa B in vivo

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

34

1 reference

High adenoviral loads stimulate NF kappaB-dependent gene expression in human vascular smooth muscle cells

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

35

1 reference

High glucose induces enhanced monocyte adhesion to valvular endothelial cells via a mechanism involving ICAM-1, VCAM-1 and CD18.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

37

1 reference

Direct demonstration of P-selectin- and VCAM-1-dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein E-deficient mice

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

38

1 reference

A major role for VCAM-1, but not ICAM-1, in early atherosclerosis

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

39

1 reference

Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-kappa B and AP-1

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

41

1 reference

Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

42

1 reference

Transcriptional activation of the macrophage-colony stimulating factor gene by minimally modified LDL. Involvement of nuclear factor-kappa B.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

43

1 reference

Involvement of NF-kappaB p50/p65 heterodimer in activation of the human pro-interleukin-1beta gene at two subregions of the upstream enhancer element

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

45

1 reference

STAT5 induces macrophage differentiation of M1 leukemia cells through activation of IL-6 production mediated by NF-kappaB p65.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

46

1 reference

Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

48

1 reference

Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

49

1 reference

Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

50

1 reference

Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

51

1 reference

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

52

1 reference

Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

53

1 reference

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

54

1 reference

C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

55

1 reference

C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

56

1 reference

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

57

1 reference

Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

58

1 reference

Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

59

1 reference

Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

60

1 reference

NAD(P)H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin II.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

61

1 reference

Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

62

1 reference

Effect of nitric oxide donors on neointima formation and vascular reactivity in the collared carotid artery of rabbits

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

63

1 reference

Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

64

1 reference

Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

65

1 reference

Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

67

1 reference

Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

68

1 reference

PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

69

1 reference

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

70

1 reference

Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

72

1 reference

Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

73

1 reference

Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

74

1 reference

PAI-1 in human hypertension: relation to hypertensive groups

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

75

1 reference

ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

76

1 reference

Hypertriglyceridemia and regulation of fibrinolytic activity

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

77

1 reference

Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

79

1 reference

Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

80

1 reference

Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

81

1 reference

Plasminogen Activator Inhibitor Type-1 Synthesis and mRNA Expression in HepG2 Cells Are Regulated by VLDL

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

82

1 reference

Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

83

1 reference

Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

84

1 reference

Aspirin in the treatment of cardiovascular disease: a review

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

85

1 reference

CHD: a major burden in type 2 diabetes

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

86

1 reference

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

87

1 reference

Endothelial dysfunction: cause of the insulin resistance syndrome

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

88

1 reference

Exercise training enhances endothelial function in young men

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

89

1 reference

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

90

1 reference

Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

91

1 reference

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

92

1 reference

Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

93

1 reference

Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

94

1 reference

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

95

1 reference

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

96

1 reference

The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

97

1 reference

Troglitazone improves endothelial dysfunction in patients with insulin resistance.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

98

1 reference

Increasing insulin sensitivity lowers blood pressure in the fructose-fed rat

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

99

1 reference

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

100

1 reference

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

101

1 reference

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

102

1 reference

hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

103

1 reference

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

104

1 reference

C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

105

1 reference

Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

106

1 reference

Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

107

1 reference

Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

108

1 reference

Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

109

1 reference

Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

110

1 reference

Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

111

1 reference

Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

112

1 reference

Ramipril and the development of diabetes.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

113

1 reference

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

114

1 reference

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

115

1 reference

Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

116

1 reference

Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure?

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

117

1 reference

Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0285

118

1 reference

2 January 2024

Identifiers

DOI

10.1210/EN.2003-0285

1 reference

6 August 2017

1 reference